Pharma: Page 34
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Organon's Chief Commercial Officer Susanne Fiedler
Susi Fiedler, chief commercial officer, was instrumental in the spinout of Organon as a standalone company focused on a broad range of women’s health issues.
By Taren Grom • Feb. 16, 2022 -
Stock via Getty Images
Q&AWinning buy-in from early stage biotech investors
The market is starting to cool down, but with the right strategies, biotechs can still attract early stage financing.
By Taren Grom • Feb. 11, 2022 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Stock via Getty Images
OpinionIndustry executives on the milestone moments shaping pharma's future
Scientific, technological, and communication changes that are making a permanent impact on the industry.
By Taren Grom • Feb. 9, 2022 -
Permission granted by Mike Rea.
Q&AInnovation vs. invention
IDEA Pharma’s indices ranks how well companies turn ideas into commercialized pharma products.
By Taren Grom • Feb. 9, 2022 -
Courtesy of Saniona
Q&ASaniona's CEO on why it takes a village to develop treatments for a rare disease
Saniona built its village by first hiring a head of patient advocacy.
By Kim Ribbink • Feb. 8, 2022 -
Courtesy of 23andMe
Q&AWhy 23andMe's first solo clinical trial is a big deal
It's the first test for a compound developed with the help of the company's genetic data — and there could be plenty more to come.
By Taren Grom • Feb. 7, 2022 -
Sergio Flores via Getty Images
Home is where the trial is
Facing pandemic disruptions, smaller biotechs are discovering the benefits and challenges of turning to decentralized clinical trials.
By Kelly Bilodeau • Feb. 7, 2022 -
Retrieved from MaxPixel.
Pharma's pain points with AI
Looking beyond the buzz and at the challenges associated with AI.
By Meagan Parrish • Feb. 7, 2022 -
Courtesy of Ferring Pharma
Ferring Pharmaceuticals president discusses the need for more funding in women's health research
Read why women's healthcare funding is such a challenge.
By Robin Robinson • Feb. 4, 2022 -
Retrieved from Google image.
OpinionIndustry executives predict the next 'blue oceans' in pharma
Where life science leaders see breakthroughs happening in the industry.
By Taren Grom • Feb. 4, 2022 -
Courtesy of Web Sun
Komodo Health's partnership with Chan Zuckerberg Initiative gives 50 rare disease patient organizations access to next-generation analytics
With 330 million patient healthcare encounters in its database, Komodo assists advocacy organizations in gaining insights on specific patient populations.
By Robin Robinson • Feb. 3, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Syneos Health's president of commercial solutions, Michelle Keefe
How Michelle Keefe, president, commercial solutions at Syneos Health, steered her team into a rapid pivot during the pandemic.
By Taren Grom • Feb. 2, 2022 -
Pekic via Getty Images
OpinionTalent acquisition stays top of mind for pharma execs
From creating flexible work environments to looking outside the industry for new talent, pharma execs are shifting strategies to keep their teams afloat.
By Taren Grom • Feb. 1, 2022 -
Retrieved from Rare Disease.org.
Q&AFor the CEO of Travere, running a rare disease company is personal
To kick off Rare Disease month, we interview the CEO of Travere Therapeutics
By Kim Ribbink • Feb. 1, 2022 -
Ricardo Ceppi via Getty Images
OpinionBiopharma's R&D leaders on how technology can accelerate drug development
How emerging digital tools are providing enhanced clinical insights and improved trial results.
By Taren Grom • Jan. 27, 2022 -
Courtesy of Sanofi
Q&ASanofi's chief scientist on why 'this is the moment' for AI in Big Pharma
How a $5.2 billion AI investment is enabling the French pharma to accelerate drug development.
By Meagan Parrish • Jan. 27, 2022 -
Justin Sullivan via Getty Images
Q&AWith its wealth of patient data, Walgreens is looking to disrupt the clinical trial space
How the mega-pharmacy’s clinical trials officer is looking to capitalize on its deep well of patient data to create an interconnected healthcare system of the future.
By Taren Grom • Jan. 26, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Janssen's Dr. Sylvie Laquerre
Why following the science is crucial when bringing new compounds to market.
By Taren Grom • Jan. 26, 2022 -
How AI is helping pharma solve some of its COVID problems
With the pressure still on pharma to innovate quickly and go digital, the use-cases for AI are increasing in stride.
By Meagan Parrish • Jan. 25, 2022 -
Permission granted by Craig Lipset
ProfileOne man's quest to boost the patient's role in clinical trials
How a personal diagnosis inspired Craig Lipset to transform patient involvement in medical research.
By Robin Robinson • Jan. 24, 2022 -
Retrieved from Google image.
OpinionLeaders predict improving patient engagement will lead to growth opportunities
Why patient engagement is key to successful business growth.
By Taren Grom • Jan. 24, 2022 -
Retrieved from Google image.
ProfileEvofem CEO Saundra Pelletier aims to level the playing field between men's and women's health
Evofem CEO and PharmaVoice100, Saundra Pelletier, discusses funding challenges for women's health.
By Alexandra Pecci • Jan. 23, 2022 -
Giuseppe Cacace via Getty Images
What the opera can teach pharma about patient communication
With his opera knowledge, Inozyme’s Director of Investor Relations Stefan Riley uses his unique perspective to tell the company's compelling story.
By Kim Ribbink • Jan. 23, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Pfizer CMO Dr. Aida Habtezion
Pfizer's CMO shares her experiences transforming the company's R&D culture and improving health equity
By Taren Grom • Jan. 19, 2022 -
Space Frontiers via Getty Images
ProfileVaxxinity looks to pioneer the next revolution in pharma
With a one-of-a-kind platform and novel candidates for major indications, Vaxxinity wants to disrupt the industry’s paradigm of success.
By Meagan Parrish • Jan. 14, 2022
Previous
